Trial: Keynote-811

KEYNOTE-811: HRQOL pembro plus tras and chemo in first-line HER2+ advanced gastric cancer

Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric Cancer

KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer

Biomarker-driven treatment strategies for HER2+ G/GEJ junction cancer

32 First Line Therapy for HER2+ GEA

Hope For Stomach Cancer

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal...

Developments in gastric and gastroesophageal cancer management

Understanding, Detecting, and Treating Gastroesophageal Junction Adenocarcinoma

Upper Gastrointestinal Cancer | 2022 OneOncology Conference

Total Health | Oncology

Advances in HER2-targeted therapies for gastric cancer

HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

PeerView Oncology

Gastroesophageal Cancer: Current Positioning of Immunotherapy

Standard-of-Care, Second-Line, and Future Therapies for GEJ and Esophageal Adenocarcinoma

Targeted Treatment Strategies: Innovative Approaches for the Management of Gastric Cancer

Gastric and GEJ cancer clinical case discussions

COR2ED The Heart of Medical Education

Chair's Take: HER2-Targeted and Other Agents for Gastric Cancer

PeerView Oncology

Treatment for Management of Advanced Metastatic Upper GI Tumors in the First Line

The Ruesch Center

Dr. Shah on the Rationale for the KEYNOTE-590 Trial in Esophageal Carcinoma

Catalysts for Change in Gastric & GEJ Cancer

PeerView Oncology

Dr. Davis on Caveats of the KEYNOTE-062 Trial Findings in Gastric/GEJ Cancer